Nephrology Fellowship and COVID-19 — NephJC
This week, we will discuss the two survey of nephrology trainees regarding their experience with training during the COVID pandemic of 2020-21.
Related Articles
Sparsentan in IgA Nephropathy : The PROTECT trial — NephJC
This week, we will discuss another IgA Nephropathy trial – Sparsentan this time. A dual endothelin antagonist and angiotensin receptor antagonist.
PubMed
PubMed® comprises more than 36 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full text…
Freely Filtered 048: Putting TESTING to the Test — NephJC
Episode 048: TESTING is the latest IgA nephropathy trial and it is the comeback kid of nephrology trials. From a trial that was halted because…
Cost-Effectiveness Analysis of Nefecon versus Best Supportive Care for People with Immunoglobulin A Nephropathy (IgAN) in the United States
To estimate the cost-effectiveness of Nefecon in addition to the best supportive care (BSC) vs BSC in a hypothetical cohort of commercially insured adult patients…
Nefecon in IgA Nephropathy, the Nefigard trial — NephJC
This week, we will discuss NEFIGARD, the trial of a targeted release steroid. It reduces proteinuria in IgA nephropathy – should it upstage humble prednisone?
Healing, Hype, or Harm: The NefIgArd trial — NephJC
This week, we will discuss the final results of the NEFIGARD trial with the GFR slope data. Is targeted release budesonide aka Nefecon really a…
Nefecon in IgA Nephropathy, the Nefigard trial — NephJC
This week, we will discuss NEFIGARD, the trial of a targeted release steroid. It reduces proteinuria in IgA nephropathy – should it upstage humble prednisone?
Freely Filtered 048: Putting TESTING to the Test — NephJC
Episode 048: TESTING is the latest IgA nephropathy trial and it is the comeback kid of nephrology trials. From a trial that was halted because…
Cost-Effectiveness Analysis of Nefecon versus Best Supportive Care for People with Immunoglobulin A Nephropathy (IgAN) in the United States
To estimate the cost-effectiveness of Nefecon in addition to the best supportive care (BSC) vs BSC in a hypothetical cohort of commercially insured adult patients…